198 related articles for article (PubMed ID: 22850947)
1. Terbinafine inhibits Cryptococcus neoformans growth and modulates fungal morphology.
Guerra CR; Ishida K; Nucci M; Rozental S
Mem Inst Oswaldo Cruz; 2012 Aug; 107(5):582-90. PubMed ID: 22850947
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of antifungal combination against Cryptococcus spp.
Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
[TBL] [Abstract][Full Text] [Related]
3. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
[TBL] [Abstract][Full Text] [Related]
4. Enhanced activity of antifungal drugs by lysozyme against Cryptococcus neoformans.
Nakamura Y; Kano R; Watanabe S; Takahashi H; Hasegawa A
Mycoses; 1998; 41(5-6):199-202. PubMed ID: 9715633
[TBL] [Abstract][Full Text] [Related]
5. In vitro antifungal activities of amphotericin B, 5-fluorocytosine, fluconazole and itraconazole against Cryptococcus neoformans isolated from cerebrospinal fluid and blood from patients in Serbia.
Trpković A; Pekmezović M; Barać A; Crnčević Radović L; Arsić Arsenijević V
J Mycol Med; 2012 Sep; 22(3):243-8. PubMed ID: 23518082
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effect of pyrvinium pamoate and posaconazole against
Li Y; Li S; Chen M; Xiao J; Fang H
Front Cell Infect Microbiol; 2022; 12():1074903. PubMed ID: 36569209
[TBL] [Abstract][Full Text] [Related]
7. Interactions between antifungals and everolimus against
Liang P; Song J; Liu Q
Front Cell Infect Microbiol; 2023; 13():1131641. PubMed ID: 37026056
[TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients.
Li L; Wang Z; Li R; Luo S; Sun X
Am J Ophthalmol; 2008 Nov; 146(5):724-8. PubMed ID: 18707669
[TBL] [Abstract][Full Text] [Related]
9. Effects of environmental factors on sensitivity of Cryptococcus neoformans to fluconazole and amphotericin B.
Carlson T; Lupinacci E; Moseley K; Chandrasekaran S
FEMS Microbiol Lett; 2021 May; 368(7):. PubMed ID: 33877319
[TBL] [Abstract][Full Text] [Related]
10. In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans.
Barchiesi F; Di Francesco LF; Compagnucci P; Arzeni D; Giacometti A; Scalise G
J Antimicrob Chemother; 1998 Jan; 41(1):59-65. PubMed ID: 9511038
[TBL] [Abstract][Full Text] [Related]
11. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. BSAC Working Party on Antifungal Chemotherapy.
Warnock DW; Johnson EM; Rogers TR
J Antimicrob Chemother; 1998 Sep; 42(3):321-31. PubMed ID: 9786472
[TBL] [Abstract][Full Text] [Related]
12. In vitro interaction of terbinafine with itraconazole, fluconazole, amphotericin B and 5-flucytosine against Aspergillus spp.
Mosquera J; Sharp A; Moore CB; Warn PA; Denning DW
J Antimicrob Chemother; 2002 Aug; 50(2):189-94. PubMed ID: 12161398
[TBL] [Abstract][Full Text] [Related]
13. [Susceptibility to antifungal agents among Cryptococcus neoformans varieties isolated from patients at a university hospital].
Silva PR; Rabelo RA; Terra AP; Teixeira DN
Rev Soc Bras Med Trop; 2008; 41(2):158-62. PubMed ID: 18545836
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of Sporothrix brasiliensis isolates to amphotericin B, azoles, and terbinafine.
Borba-Santos LP; Rodrigues AM; Gagini TB; Fernandes GF; Castro R; de Camargo ZP; Nucci M; Lopes-Bezerra LM; Ishida K; Rozental S
Med Mycol; 2015 Feb; 53(2):178-88. PubMed ID: 25394542
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents.
Aller AI; Martín-Mazuelos E; Gutiérrez MJ; Bernal S; Chávez M; Recio FJ
J Antimicrob Chemother; 2000 Dec; 46(6):997-1000. PubMed ID: 11102421
[TBL] [Abstract][Full Text] [Related]
16. A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology.
Burgess DS; Hastings RW
Diagn Microbiol Infect Dis; 2000 Oct; 38(2):87-93. PubMed ID: 11035239
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.
Kantarcioğlu AS; Boekhout T; Yücel A; Altas K
Med Mycol; 2009 Mar; 47(2):169-76. PubMed ID: 18654925
[TBL] [Abstract][Full Text] [Related]
18. Impact of iron chelators on growth and expression of iron-related genes of Cryptococcus species.
Chayakulkeeree M; Tangkoskul T; Waywa D; Tiengrim S; Pati N; Thamlikitkul V
J Mycol Med; 2020 Apr; 30(1):100905. PubMed ID: 31706700
[TBL] [Abstract][Full Text] [Related]
19. In vitro interaction of antifungal and antibacterial drugs against Cryptococcus neoformans var. grubii before and after capsular induction.
Rossato L; Loreto ÉS; Venturini TP; Azevedo MI; Weiblen C; Botton SA; Santurio JM; Alves SH
Med Mycol; 2015 Nov; 53(8):885-9. PubMed ID: 26333356
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.
Rodero L; Córdoba S; Cahn P; Hochenfellner F; Davel G; Canteros C; Kaufman S; Guelfand L
J Antimicrob Chemother; 2000 Feb; 45(2):239-42. PubMed ID: 10660509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
